Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data
Six days after Genentech rolled out disappointing early-stage data on its IDO1 drug GDC-0919 (navoximod) in-licensed from NewLink Genetics, the big Roche subsidiary is kicking it out of the pipeline.
NewLink $NLNK announced that Genentech has handed back all rights to the drug, though its discovery partnership continues. The cancer drug specialist is walking away from a $1 billion-plus deal that was inked with $150 million upfront.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.